Dianthus Therapeutics, Inc.
DNTH- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001690585
In the last 90 days, Dianthus Therapeutics, Inc. insiders filed 0 open-market purchases and 8 sales; 269 institutions reported holding it in 13F filings for Q2 2026, worth $6.40B in total; no superinvestor holds it.
Q4 2023 vs. Q3 2023
How the institutions holding Dianthus Therapeutics, Inc. changed between Q3 2023 and Q4 2023.
All holders in Q4 2023All holders in Q3 2023
| Measure | Q3 2023 | Q4 2023 | Change |
|---|---|---|---|
| Holders | 30 | 39 | +9 |
| Shares | 10.1M | 10.3M | +218.5K (+2.2%) |
| Value | $136.3M | $106.5M | −$29.8M (−21.9%) |
New holders (10)
Institutions that held Dianthus Therapeutics, Inc. at the end of Q4 2023 but not at the end of Q3 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Vestal Point Capital, LP | 135,000 | $1.40M | 0.15% |
| Fred Alger Management, LLC | 40,841 | $424.7K | 0.00% |
| Millennium Management LLC | 33,964 | $353.2K | 0.00% |
| Susquehanna International Group, LLP | 28,679 | $298.3K | 0.00% |
| Jane Street Group, LLC | 15,678 | $163.1K | 0.00% |
| Northern Trust Corp | 15,301 | $159.1K | 0.00% |
| Dimensional Fund Advisors LP | 14,736 | $153.3K | 0.00% |
| Tower Research Capital LLC (TRC) | 2,430 | $25.3K | 0.00% |
| ADAR1 Capital Management, LLC | 481 | $5.00K | 0.00% |
| Barclays PLC | 3 | $31 | 0.00% |
Sold out (1)
Institutions that held Dianthus Therapeutics, Inc. at the end of Q3 2023 and filed for Q4 2023 without it.
| Institution | Shares, Q3 2023 | Value, Q3 2023 |
|---|---|---|
| Citadel Advisors LLC | 105,561 | $1.44M |